Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This Phase I study is designed to assess the pharmacokinetics of saxagliptin and its pharmacologically active metabolite, BMS-510849, following single and multiple oral doses of 5 mg saxagliptin in healthy Chinese subjects.

Inclusion Criteria:

• Men or women (not of childbearing potential) of Chinese ethnicity
• Weigh at least 50 kg and have a body mass index (BMI) between 19 and 24 kg/m2
• Must have normal physical examination, laboratory values, ECG, pulse and blood pressure unless the investigator considers an abnormality to not be clinically significant.

Exclusion Criteria:

• History of clinically significant hypoglycaemia (low blood sugar levels)
• Women who are pregnant or breastfeeding